That's because the goal of the company was to evaluate the use of nirogacestat for the treatment of adults with relapsed/refractory ovarian granulosa cell tumors (OvGCTs) in a phase 2 open-label ...

The drug is also in mid-stage clinical development for ovarian granulosa cell tumors, a rare type of ovarian cancer that currently has no FDA-approved therapies. Through partnerships, the twice ...

is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. Shares of SWTX stock traded down $0.40 on Friday ...

is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. Shares of NASDAQ:SWTX traded down $0.21 during ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Princess Margaret Cancer Center at University Health Network-led researchers constructed a detailed single-cell atlas of ...

A team of researchers led by Dr. Rod Bremner at the Lunenfeld-Tanenbaum Research Institute, Sinai Health in Toronto, has made a significant breakthrough in understanding cancer susceptibility. Their ...

T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, according to ...

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and ...